GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » MusclePharm Corp (OTCPK:MSLPQ) » Definitions » Return-on-Tangible-Equity

MusclePharm (MusclePharm) Return-on-Tangible-Equity : 0.00% (As of Mar. 2022)


View and export this data going back to 2008. Start your Free Trial

What is MusclePharm Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MusclePharm's annualized net income for the quarter that ended in Mar. 2022 was $-25.20 Mil. MusclePharm's average shareholder tangible equity for the quarter that ended in Mar. 2022 was $-35.14 Mil. Therefore, MusclePharm's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2022 was N/A%.

The historical rank and industry rank for MusclePharm's Return-on-Tangible-Equity or its related term are showing as below:

MSLPQ's Return-on-Tangible-Equity is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 7.51
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

MusclePharm Return-on-Tangible-Equity Historical Data

The historical data trend for MusclePharm's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MusclePharm Return-on-Tangible-Equity Chart

MusclePharm Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - Negative Tangible Equity -

MusclePharm Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity - - - -

Competitive Comparison of MusclePharm's Return-on-Tangible-Equity

For the Packaged Foods subindustry, MusclePharm's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MusclePharm's Return-on-Tangible-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, MusclePharm's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where MusclePharm's Return-on-Tangible-Equity falls into.



MusclePharm Return-on-Tangible-Equity Calculation

MusclePharm's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2021 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=-12.866/( (-24.775+-32.226 )/ 2 )
=-12.866/-28.5005
=N/A %

MusclePharm's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2022 )  (Q: Dec. 2021 )(Q: Mar. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2022 )  (Q: Dec. 2021 )(Q: Mar. 2022 )
=-25.204/( (-32.226+-38.055)/ 2 )
=-25.204/-35.1405
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2022) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


MusclePharm  (OTCPK:MSLPQ) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


MusclePharm Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of MusclePharm's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


MusclePharm (MusclePharm) Business Description

Traded in Other Exchanges
N/A
Address
6728 W. Sunset Road, Suite 130, Las Vegas, NV, USA, 89118
MusclePharm Corporation is a performance lifestyle company. It develops, manufactures, markets and distributes branded nutritional supplements. It offers various types of powders, capsules, tablets and gels. Geographically, the firm has its business presence across the region of US and in the international market of which the US accounts for the majority of revenue. MusclePharm's Hybrid series products include Assault, Combat Protein Powder, BCAA 3:1:2, CLA Core, Fish Oil, Combat Crunch Protein Bars, glutamine, carnitine, Combat Crunch, Protein Crisp, Organic Protein, and Protein Cookie. The group sells its products to various fitness enthusiasts, such as professional, combat sport, weight training, bodybuilding, running, and various team and individual sports, and others.
Executives
Eric Chin officer: Chief Accounting Officer 1668 S. GARFIELD AVE., 2ND FLOOR, ALHAMBRA CA 91801
Paul W Karr director BRISTOL MEYERS SQUIBB CO, 345 PARK AVENUE, NEW YORK NY 10154
Sabina Rizvi officer: President & CFO 6728 W. SUNSET ROAD, SUITE 130, LAS VEGAS NV 89118
Michael David Heller director 4500 PARK GRANADA, SUITE 202, CALABASAS CA 91302
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Donald Feagan 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Amerop Holdings, Inc. 10 percent owner 1800 BROADWAY, SUITE 100, BOULDER CO 80302
White Winston Select Asset Fund Series Fund Mp-18, Llc 10 percent owner C/O WHITE WINSTON SELECT ASSET FUNDS, LLC, 265 FRANKLIN ST., SUITE 1702, BOSTON MA 02110
Robert P Mahoney 10 percent owner 4 DANIELS FARM ROAD, #305, TRUMBULL CT 06611
White Winston Select Asset Funds, Llc 10 percent owner 265 FRANKLIN STREET, SUITE 1702, BOSTON MA 02110
Todd M. Enright 10 percent owner 2150 SOUTH 1300 EAST STREET, SUITE 500, SALT LAKE CITY UT 84106
Mark Blundell 10 percent owner 8 MACDONALD AVE, ARMOUK NY 10504
John J Desmond director 10 GLEN HEAD ROAD, GLEN HEAD NY 11545
Wynnefield Small Cap Value Offshore Fund Ltd 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123
Wynnefield Capital Inc 10 percent owner 450 SEVENTH AVE, STE 509, NEW YORK NY 10123